Skip to content

Allen & Overy`s Life Sciences team advises Vision Healthcare on the acquisition of AixSwiss

Allen & Overy has advised Vision Healthcare, a Belgium-based consumer healthcare company with a large portfolio of self-care brands and over-the-counter products in several European countries, on the acquisition of 100% of the shares in AixSwiss BV (AixSwiss).

AixSwiss, established in 2015 and headquartered in the Netherlands, is a leading probiotic nutraceutical supplement provider, operating under the “nupure” brand mainly through online D2C, Amazon International marketplaces and e-pharma channels predominantly in Germany, Switzerland and Austria. Nupure’stop probiotic nutraceutical supplements are mainly in the gastrointestinal (Probaflor), skin health (Probaderm, Probariasis, Lactoglow, Probaskin), oral health (Probadent) and women’s health (Lactointim) areas.

Vision Healthcare’s overall VMS, nutraceutical & digital expertise combined with AixSwiss’ probiotic expertise, will create the perfect synergetic play to unlock new growth opportunities for the nupure brand. At the same time, AixSwiss’ digital omni-channel know-how will also open new growth avenues for the Vision Healthcare brand portfolio. The acquisition is in line with Vision Healthcare’s ambitious strategy to further expand its leading digital omni-channel platform of VMS & Nutraceutical products in Europe and reinforces Vision Healthcare portfolio focus on attractive growth segments.

Allen & Overy´s extensive life sciences expertise across all sectors ensured a deep understanding of the commercial challenges and the regulatory environment, in particular European food and food supplement regulations. The German based Life Sciences team comprises about 20 specialist lawyers covering the full spectrum of legal topics and operates on a cross-border basis. The international Life Sciences team comprises more than 90 lawyers with a deep understanding and technical knowledge of the entire industry.

The Allen & Overy team which advised on all legal, including regulatory, aspects was led by partner Dr Alexander Veith and associate Adriana Worms (both Corporate/M&A/Life Sciences, Munich). The team also included Counsel Eda Zhuleku (Life Sciences/Regulatory, all Munich), senior associates Catharina Glugla (Data) and Anna Kraeling (IP, both Dusseldorf) as well as associates Florian Preinfalk, Hannah Wohlfarth (both Corporate/M&A/Life Sciences, both Munich), Merle Herrmann (Employment & Benefits) and Dr Katharina Hillmer (Antitrust, both Hamburg).

Additional advice on Dutch law matters was given by partner Jasper de Jong (Corporate/M&A), counsel Frank Doornik, associates Mirte Miltenburg, Chelsea Gunning (all Employment/Pensions) and Jari Bakx (Corporate/M&A). Partner Sophie Roozendaal and consultant Astrid Kepper advised on notary matters (all Amsterdam).